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Whilst fundamental to human survival, oxygen is harmful in excess and it is possible 
that as intensive care specialists, we focus less attention on its use than might be 
expected by the public and patients that we treat (1). In a clinical environment where 
it is rare to not administer oxygen to a patient, one would have presumed that we 
would be awash with evidence and guidance about its use. Surely decades of clear 
and indisputable findings must underpin how we use the most commonly 
administered drug in intensive care units the world over. Not so, it would seem. Huge 
variation in practice can be demonstrated (2, 3) and whilst harder to quantify, there is 
undoubtedly a wide spectrum of beliefs underpinning this inconsistency. It is our 
belief that each and every patient requires careful assessment and individualised 
oxygen titration to achieved desired targets, rather than having universal “one-size-
fits-all” prescription imposed upon them. What is lacking though, is the evidence on 
which to base clinical guidance. So, we find ourselves in an awkward position; too 
little oxygen is harmful, too much oxygen is harmful, but we are uncertain what the 
right amount of oxygen that each individual critically ill patient requires? 
 
The neurological consequences of hyperbaric oxygen toxicity were demonstrated by 
Paul Bert at the end of the 19th century (4) and the ED50 of oxygen has been 
estimated at 5.3 atmospheres (in mice) (5). Not long after Bert’s work, James Lorrain 
Smith conducted a similar set of animal experiments focusing on how the lungs 
tolerate hyperoxia (6). Unlike Bert though, Smith added in experimental conditions 
below one atmosphere in pressure, but with a greater oxygen partial pressure than 
room air. When two mice were place in 73.6% of an atmosphere of oxygen he 
reported that “On the fourth day of the experiment, one mouse was found dead, and 
when examined showed congestion and consolidation of the lungs.” The other 
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mouse survived to day nine but and then unfortunately died of an “accidental cause.” 
Similar results were seen at 79.9% of an atmosphere of oxygen; again, a 50% 
mortality rate was reported by day four. Smith made the following profound 
conclusion: “The experiments just described show that at a tension a good deal 
higher than that of ordinary air, oxygen has the effect on the lungs of an irritant, and 
produces inflammation.” These words echoed Joseph Priestly’s statement of 1774 
“…for, as a candle burns out much faster in dephlogisticated than in common air, so 
we might, as may be said, live out too fast and the animal powers be too soon 
exhausted in this pure kind of air” (7). In the time that has passed since oxygen’s 
discovery, our understanding of human physiology has expanded enormously and 
molecular biology techniques have opened our eyes to intricate but invisible 
biochemical mechanisms that govern what Smith observed over one hundred years 
ago. During oxidative phosphorylation, enzyme complexes on the inner 
mitochondrial membrane (primarily complex three, and to a lesser extent complex 
one) release superoxide radicals (O2−) from molecular oxygen (dioxygen). This 
source of endogenous reactive oxygen species (ROS) in turn forms hydrogen 
peroxide (H2O2) and the hydroxyl radical (•OH). At low concentration these molecules 
perform vital messenger roles, including cellular oxygen sensing, but in excess they 
have destructive qualities leading to breakdown of mitochondrial DNA and 
membrane structures, then cellular DNA, protein and lipids. The law of mass action 
dictates that increasing oxygen availability to the respiratory chain produces more 
ROS: raising the ambient partial pressure of oxygen from <4 kPa to as little as 10kPa 
in a cell culture environment increases H2O2 production several hundred fold (8). 
These findings readily explain Smith’s 50% murine mortality rate at an equivalent 
oxygen concentration of greater than approximately 70%.  
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The majority of drugs with a narrow therapeutic index are carefully titrated according 
to some measure of drug level or effectiveness. Considerable time and resources 
are invested in ensuring the optimum dose of insulin, heparin, aminoglycoside 
antibiotics, immunosuppressants, anticonvulsants, and antiarrhythmics, amongst 
many others. To some extent, we pay respect to this paradigm when administering 
oxygen by measuring peripheral oxygen saturation (SpO2) and the arterial partial 
pressure of oxygen (PaO2). But perhaps because this “drug” is also abundant in the 
air we breathe (20.95% of it currently (9)), we may have become complacent in the 
way that we titrate it. Rightly or wrongly, our fear of hypoxaemia far outweighs our 
appreciation of the harmful effects of hyperoxaemia, which tends to lead to 
prescriptions that reflect this prejudice, for example “maintain SaO2 >95%” or “PaO2 
> 8 kPa.” Furthermore, the ceiling effect inherent in pulse oximetry may further 
contribute to this tendency to hyperoxaemia: a low SaO2 clearly indicates 
hypoxaemia, but an SaO2 of 100% is consistent with a PaO2 as low as 14 kPa or as 
high as >80 kPa. Is this precision medicine in the 21st century?  
 
Over the last few years a number of specialties have reconsidered oxygen therapy 
for a range of conditions, bringing into question the traditional approach that if all 
else fails, just make sure you give oxygen, and plenty of it. For decades, we chose to 
ignore the fundamental physiological principle that hyperoxaemia leads to profound 
coronary artery vasoconstriction and persevered with the intuitively appealing (but 
fundamentally incorrect) notion that providing high concentration oxygen to patients 
with an acute myocardial infarction would increase the amount of oxygen delivered 
to the myocardium and preserve cellular metabolic homeostasis. Any physiology 
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undergraduate of worth might have spotted the flaw in this well-intended strategy; 
increasing the fractional inspired oxygen concentration (FIO2) from 0.21 to 1.0 only 
raises arterial oxygen content by small proportion (because haemoglobin is already 
nearly fully saturated). This century old practice has, until recently, not been 
vigorously challenged despite a publication in JAMA in 1950 suggesting that 
administering 100% oxygen to patients with myocardial infarction or angina pectoris 
could be harmful (10). Many other expert commentators have also held this view and 
it is only since publication of the AVOID trial in 2015, that practice is finally changing 
to reduce unnecessary exposure to supplemental oxygen (11).  
 
So, where are we today in terms of oxygen use in the critically ill? It would appear 
that a recent surge in interest has moved us forwards, but there remains a long way 
to go. Retrospective analysis of critical care data has shown that hyperoxaemia is 
potentially harmful in a number of conditions commonly dealt with on our units (12, 
13). Whilst it may be challenging to test the causal nature of this relationship in a 
randomised prospective manner, it is important that we take on this challenge for the 
benefit of future patients. Given the wealth of observational data suggesting harm 
from hyperoxaemia and the epidemiological data suggesting that this is 
commonplace in clinical practice, we must overcome concerns about the ethics of 
deliberately exposing patients to higher levels of inspired oxygen. Moreover, the 
concept of ‘permissive hypoxaemia’ has undergone some preliminary exploration 
and thus far has been shown to be both feasible and safe (14–16). Allowing critically 
ill patients to be managed with an SpO2 lower than usually tolerated (commonly in 
the range of 88-92%) would therefore appear to merit further investigation on a 
larger scale.  Two studies are currently in progress that are attempting to address 
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this and their results will be of great value in an area of our practice that is otherwise 
devoid of evidence. One recently published study requires more than a passing 
mention. In a single centre study conducted in Italy over approximately two and a 
half years, critically ill patients were randomised into one of two oxygenation groups 
(17). The ‘conservative’ oxygenation group had their PaO2 maintained between 9.3-
13.3 kPa or an SpO2 of 94% - 98%, whilst the control group conformed to ‘standard 
ICU practice’ defined as a PaO2 up to 20 kPa or SpO2 values between 97% and 
100%. In the control group, oxygen was administered at a minimum FIO2 of 0.4 and 
if SpO2 fell below 95% - 97%, the FIO2 was increased to reach the target value of 
SpO2. A total of 434 patients were studied and included in a “modified intent-to-treat 
analysis.” The investigators achieved good separation of oxygenation between the 
two study cohorts, with a daily time-weighted PaO2 averages of 13.6 kPa in the 
standard group and 11.6 kPa the conservative group. The primary outcome of this 
study was ICU mortality, and the values reported were: 11.6% in the conservative 
group and 20.2% in the conventional group, giving an absolute risk reduction of 8.6% 
(1.7-15.0%). Impressive figures for such a simple intervention, comparable to those 
achieved in van den Berghe et al’s intensive insulin therapy (18) and Rivers et al’s 
goal-directed therapy studies (19). However, the ‘modified intent-to-treat’ method 
used in this study involved only analysing data from those patients receiving the 
intervention for greater than 72 hours, therefore excluding some patients post-
randomisation and introducing a significant source of bias into the study results. 
Other issues raised in an editorial that accompanied the publication of this study 
include: baseline imbalances between groups at the time of randomisation favouring 
the conservative oxygen group; early termination of the study following an unplanned 
interim analysis; and the low ratio of event to participants in each group (25/216 
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deaths in the conservative group), increasing the likelihood of a false-positive result 
(20). Perhaps, though, the most pertinent thing to consider is whether 13.6 kPa vs. 
11.6 kPa is a study of permissive hypoxaemia, or one of permissive hyperoxaemia. It 
should be highlighted that the authors completed this study in the face of huge 
adversity, as an Earthquake caused substantial damage to the hospital in which 
participants were being recruited from (17).  
 
Conclusion  
The life-cycle of many critical care interventions to support physiology follows a 
predictable pattern. Initial excitement about life-saving potential, linked with the logic 
that if a bit of something is good, then more may well be better, leads to widespread 
and aggressive adoption. Time, experience and clinical trials data result in 
moderation of this approach over time, such that we arrive at a point where we avoid 
both excessive and inadequate therapy. Excellent examples of this phenomenon 
include renal replacement therapy, target arterial carbon dioxide levels and tidal 
volumes used in mechanical ventilation; in each case we have moved to a more 
measured approach. Perhaps we are now in the process of following this same path 
for oxygen therapy, moving away from the notion that more is always better, and 
instead giving the least amount necessary, thereby avoiding the harms associated 
with excess and inadequate therapy. Like Goldilocks, we need to avoid too much 
and too little oxygen, and aim for ‘just right’.  
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